Patents by Inventor Oleg Borisovich Maximov

Oleg Borisovich Maximov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histochrome and its therapeutic use in acute myocardial infarction and ischemic heart disease
    Patent number: 6410601
    Abstract: A pharmaceutical composition is provided, which comprises an aqeous solution containing a mixture of di- and tri-sodium salts of echinochrome in an amount of 0.90 to 1.10 g/ml (Histochrome). It meets the requirements that apply to injectable formulations. Administration of Histochrome reduces by 57% the necrosis zone in patients with acute myocardial infarction, restores the contractility of the left ventricle, reduces the incidence of reperfusion-induced ventricular arrhythmias and exerts an antiarrhythmogenic effect. Histochrome suppresses the aggregation of erythrocytes and thrombocytes, produces a beneficial effect on the clinical course of the disease, reduces the incidence of complications and lethal outcomes in cases of acute myocardial infarction. It is well tolerated by patients.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: June 25, 2002
    Assignee: Tikhookeansky Institut Bioorganicheskoi Khimii Dalnevostochnogo Otdeleniya Rossiiskoi Akademii Nauk
    Inventors: Georgy Borisovich Elyakov, Oleg Borisovich Maximov, Natalya Petrovna Mischenko, Evgenia Alexandrovna Koltsova, Sergei Alexandrovich Fedoreev, Ljutsia Ignatievna Glebko, Natalya Petrovna Krasovskaya, Alexandr Alexeevich Artjukov
  • Histochrome and its therapeutic use in ophthalmology
    Patent number: 6384084
    Abstract: A pharmaceutical composition is provided which comprises an isotonic solution of an 0.02% mixture of di- and trisodim salts of echinochrome (Histochrome). It meets the requirements that apply to injectable formulations. Histochrome administration to human patients normalizes metabolic processes and eliminates inflammation in the retina, vascular membrane and cornea of the eye, improves trophic functions, reduces edema and accelerates epithelization.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: May 7, 2002
    Assignee: Tikhookeansky Institut Bioorganicheskoi Khimii Dalnevostochnogo Otdeleniya Rossiiskoi Akademii Nauk
    Inventors: Georgy Borisovich Elyakov, Oleg Borisovich Maximov, Natalya Petrovna Mischenko, Evgenia Alexandrovna Koltsova, Sergei Alexandrovich Fedoreev, Ljutsia Ignatievna Glebko, Natalya Petrovna Krasovskaya, Alexandr Alexeevich Artjukov
  • Histochrome and its therapeutic use in acute myocardial infarction and ischemic heart disease
    Publication number: 20010029270
    Abstract: A pharmaceutical composition is provided, which comprises an aqeous solution containing a mixture of di- and tri-sodium salts of echinochrome in an amount of 0.90 to 1.10 g/ml (Histochrome). It meets the requirements that apply to injectable formulations. Administration of Histochrome reduces by 57% the necrosis zone in patients with acute myocardial infarction, restores the contractility of the left ventricle, reduces the incidence of reperfusion-induced ventricular arrhythmias and exerts an antiarrhythmogenic effect. Histochrome suppresses the aggregation of erythrocytes and thrombocytes, produces a beneficial effect on the clinical course of the disease, reduces the incidence of complications and lethal outcomes in cases of acute myocardial infarction. It is well tolerated by patients.
    Type: Application
    Filed: April 12, 2001
    Publication date: October 11, 2001
    Inventors: Georgy Borisovich Elyakov, Oleg Borisovich Maximov, Natalya Petrovna Mischenko, Evgenia Alexandrovna Koltsova, Sergei Alexandrovich Fedoreev, Ljutsia Ignatievna Glebko, Natalya Petrovna Krasovskaya, Alexandr Alexeevich Artjukov
  • Histochrome and its therapeutic use in ophthalmology
    Publication number: 20010021723
    Abstract: A pharmaceutical composition is provided which comprises an isotonic solution of an 0.02% mixture of di- and trisodim salts of echinochrome (Histochrome). It meets the requirements that apply to injectable formulations. Histochrome administration to human patients normalizes metabolic processes and eliminates inflammation in the retina, vascular membrane and cornea of the eye, improves trophic functions, reduces edema and accelerates epithelization.
    Type: Application
    Filed: April 12, 2001
    Publication date: September 13, 2001
    Inventors: Georgy Borisovich Elyakov, Oleg Borisovich Maximov, Natalya Petrovna Mischenko, Evgenia Alexandrovna Koltsova, Sergei Alexandrovich Fedoreev, Ljutsia Ignatievna Glebko, Natalya Petrovna Krasovskaya, Alexander Alexeevich Artjukov